Omvoh™ (mirikizumab-mrkz) Intravenous

EviCore covers IV Omvoh (mirikizumab‑mrkz) only as induction therapy for adults (≥18) with moderately to severely active ulcerative colitis (pediatric use and maintenance beyond a 3‑month approval are excluded). Approval requires documentation of age and induction intent, prescription by or in consultation with a gastroenterologist, and prior trial of at least one systemic UC agent (e.g., adalimumab, infliximab, golimumab, ustekinumab, azathioprine, 6‑MP, cyclosporine, tacrolimus, or a corticosteroid); for pouchitis, a trial of a specified local therapy (antibiotic, probiotic, corticosteroid or mesalamine enema) is required, and mesalamine products or biosimilars do not count as prior systemic therapy.

"Omvoh is indicated for the treatment of moderately to severely active ulcerative colitis in adults."

Sign up to see full coverage criteria, indications, and limitations.